A1 Refereed original research article in a scientific journal
KLF6 IVS1 -27G > A variant and the risk of prostate cancer in Finland
Authors: Seppala EH, Autio V, Duggal P, Ikonen T, Stenman UH, Auvinen A, Bailey-Wilson JE, Tammela TLJ, Schleutker J
Publisher: ELSEVIER SCIENCE BV
Publication year: 2007
Journal: European Urology
Journal name in source: EUROPEAN UROLOGY
Journal acronym: EUR UROL
Volume: 52
Issue: 4
First page : 1076
Last page: 1081
Number of pages: 6
ISSN: 0302-2838
DOI: https://doi.org/10.1016/j.eururo.2006.11.019
Abstract
Objectives: A recent report demonstrated that KLF6 IVS1 -27G > A substitution increases the transcription of alternatively spliced isoforms; this action was suggested to be associated with prostate cancer (pCA). To evaluate these findings among the Finnish population, a total of 3348 samples were analysed.Methods: The variant was genotyped in 164 patients with familial pCA, 852 patients with unselected pCA, 459 patients with benign prostate hyperplasia (BPH), 923 male population controls, and 950 men from a Finnish prostate- specific antigen (PSA) screening trial with PSA levels less than 1.0 ng/ml. Odds ratios (ORs) and corresponding 95% confidence intervals (95%CIs) were calculated by using logistic regression to estimate pCA risk.Results: Association testing revealed no significant differences between familial prostate cancer patients and population controls (OR: 0.84; 95%CI, 0.56-1.28; p = 0.42), unselected cases and controls (OR: 0.95; 95%CI, 0.76-1.19; p = 0.63), or BPH cases and controls (OR: 1.12; 95%CI, 0.86-1.46; p = 0.39). pCA and BPH cases were also compared with PSA-screened controls. None of these analyses revealed any significant associations.Conclusion: Our results do not support the suggested association of KLF6 IVS1 -27G > A germline polymorphism with pCA risk and also suggest that the variant is not a risk allele for BPH in the Finnish population.
Objectives: A recent report demonstrated that KLF6 IVS1 -27G > A substitution increases the transcription of alternatively spliced isoforms; this action was suggested to be associated with prostate cancer (pCA). To evaluate these findings among the Finnish population, a total of 3348 samples were analysed.Methods: The variant was genotyped in 164 patients with familial pCA, 852 patients with unselected pCA, 459 patients with benign prostate hyperplasia (BPH), 923 male population controls, and 950 men from a Finnish prostate- specific antigen (PSA) screening trial with PSA levels less than 1.0 ng/ml. Odds ratios (ORs) and corresponding 95% confidence intervals (95%CIs) were calculated by using logistic regression to estimate pCA risk.Results: Association testing revealed no significant differences between familial prostate cancer patients and population controls (OR: 0.84; 95%CI, 0.56-1.28; p = 0.42), unselected cases and controls (OR: 0.95; 95%CI, 0.76-1.19; p = 0.63), or BPH cases and controls (OR: 1.12; 95%CI, 0.86-1.46; p = 0.39). pCA and BPH cases were also compared with PSA-screened controls. None of these analyses revealed any significant associations.Conclusion: Our results do not support the suggested association of KLF6 IVS1 -27G > A germline polymorphism with pCA risk and also suggest that the variant is not a risk allele for BPH in the Finnish population.
UTU Research Portal